Researchers at Johns Hopkins University have recently determined that a number of incretin mimetic diabetes medications like Byetta, Januvia/Janumet and Victoza could be linked to pancreatitis and pancreatic cancer.
A motion to consolidate the incretin mimetic cases into one MDL is currently pending. The Judicial Panel on Multidistrict Litigation (JPML) will likely hear oral argument, if necessary, this summer or fall. If granted, the MDL will likely be venued in the Southern District of California where Judge Anthony J. Battaglia is already overseeing a number of cases. Plaintiffs have alleged that the manufacturers knew of the cancer risk associated with the incretin mimetics, but failed to disclose it to the medical community and/or consumers. Reports indicate there are approximately 500 cases ready for filing. It is expected that there could eventually be thousands of plaintiffs nationwide.
If you feel you have experienced any side-effects from taking Byetta, Januvia/Janumet or Victoza, you can contact Stark & Stark and speak to one of the Mass Tort/Pharmaceutical Litigation attorneys, free of charge, who can help assess any claims that you might have against the Byetta, Januvia/Janumet or Victoza manufacturers.
 One report indicates that the defendant manufacturers have consented to MDL status in the Southern District of California.